Skip to content
Back to explorer
Printable monograph

IDH2 inhibitor

Enasidenib

Idhifa · Enasi

IDH2 inhibitor · approved 2017 · 8 citations

Up to date· through 2025
Fairly sourced4/9 · 4 signals
  • Met: 8 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 8y)
  • Met: Beyond single case reports
  • Not met: Peer-reviewed sources
  • Met: Landmark reference
  • Met: Current through 2025
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

An IDH2 inhibitor that cures by forcing leukemic blasts to mature — and that maturation itself can flood the kidneys.

ModerateIDH2 inhibitor
IDH2-mutated relapsed/refractory AML

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Highly protein-bound, hepatically metabolized IDH2 inhibitor not expected to be appreciably removed by hemodialysis; no dedicated renal dose adjustment and no HD-specific dosing guidance, with modifications driven by toxicity not CrCl.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: Idhifa, Jan 2025. Not necessarily about the kidney. FDA label section.
§01

Signature kidney injury

Representative incidence10%

IDH-inhibitor differentiation syndrome (the main route to AKI) occurs in roughly 10% of enasidenib-treated AML patients (10.4% any-grade in a pooled trial analysis; ~7% grade ≥3 in the first-in-human study). Tumor lysis is a secondary risk. Direct tubular nephrotoxicity is not well quantified.Source: Montesinos et al., Blood Adv 2024 (10.4% any-grade)

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Differentiation syndrome typically appears days to weeks after starting, with a median onset around 30 days and a reported range from days to roughly 4-5 months.

Distilled from: “Differentiation syndrome typically days to weeks after starting (median onset ~30 days; reported range days to ~4–5 months).”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Prerenal / Hemodynamic AKI#1 · Signatureno population incidence denominator · drug-level figure in §01

    IDH2-inhibitor differentiation syndrome (fluid retention, capillary leak -> prerenal/hemodynamic AKI) occurred as a grade 3-4 enasidenib-related event in 7% of relapsed/refractory AML patients. PMID 28588020 (opens PubMed in a new tab)

  2. Acute Tubular NecrosisSecondaryqualitative — no citable incidence

    Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.

  3. Electrolyte DisturbanceSecondaryqualitative — no citable incidence

    Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

10%incidence

Representative incidence

SeverityModerate
ReversibilityReversible
Evidence8 citations
Nephron map

Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.

Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.

Vasculature / Endothelium — not involved
Proximal Tubule — not involved
Distal Tubule / Collecting Duct — not involved

Prerenal / Hemodynamic AKI

Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

Drug-induced differentiation of IDH2-mutant blasts triggers a cytokine-driven systemic inflammatory (differentiation) syndrome with capillary leak, fluid shifts, hypotension and weight gain, producing hemodynamic (prerenal) AKI that can progress to ischemic ATN. Concurrent rapid cytoreduction can release urate/phosphate and add tumor-lysis intratubular injury; hyperleukocytosis amplifies the inflammatory cascade.

Clinical presentation

Differentiation syndrome with dyspnea/hypoxia, pulmonary infiltrates, fever, peripheral edema, weight gain, pleural/pericardial effusions and a rising creatinine; sometimes hyperuricemia/hyperphosphatemia/hyperkalemia from tumor lysis. Indirect hyperbilirubinemia (UGT1A1 inhibition) is a characteristic accompanying lab finding but is not renal.

Management

Start dexamethasone (e.g., 10 mg IV q12h) at first suspicion of differentiation syndrome; supportive hemodynamics, diuresis for fluid overload and oxygen. Hold enasidenib for severe/refractory syndrome and resume once resolved. Manage tumor lysis with IV hydration and rasburicase or allopurinol; correct electrolytes.Lesion-level management framework

Risk factors

  • High bone-marrow or peripheral blast burden
  • Hyperleukocytosis
  • Elevated LDH
  • Rapid leukemic response
  • Volume depletion

Prevention

  • Vigilance for early differentiation-syndrome symptoms
  • Prompt corticosteroids at first suspicion
  • Cytoreduction (e.g., hydroxyurea) for hyperleukocytosis
  • TLS prophylaxis with hydration and urate-lowering therapy
Anticancer mechanism· how it treats cancer

Oral, first-in-class allosteric inhibitor of mutant isocitrate dehydrogenase-2 (IDH2). Mutant IDH2 neomorphically converts α-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2-HG), which causes DNA/histone hypermethylation and blocks myeloid differentiation; enasidenib lowers 2-HG and releases this block, driving leukemic blasts to terminally mature in IDH2-mutated acute myeloid leukemia (AML).

Note · Renal injury is a downstream consequence of differentiation syndrome and tumor lysis rather than direct tubular toxicity. Inducing differentiation (not cytotoxicity) is the therapeutic mechanism, so the same biology that drives response drives the renal risk.
§04

Clinical depth

Renal dose adjustment

No dedicated renal dose adjustment is established; enasidenib was not studied in severe renal impairment/ESKD. Standard dose is 100 mg orally once daily, modified for toxicity (including differentiation syndrome and indirect hyperbilirubinemia), not for CrCl.

Dialyzability & ESKD dosing

Not characterized; enasidenib is highly protein-bound and hepatically metabolized, so it is not expected to be appreciably removed by hemodialysis. No HD-specific dosing guidance exists.

Differential diagnosis

Distinguish differentiation syndrome from sepsis/pneumonia (overlapping fever, infiltrates, hypotension), cardiogenic pulmonary edema, and transfusion reactions; the constellation of weight gain, effusions and rising WBC during blast maturation favors differentiation syndrome. Separate prerenal/differentiation AKI from tumor-lysis crystal nephropathy by the electrolyte/uric-acid profile.

Monitoring

  • Daily symptom/weight/oxygenation assessment for differentiation syndrome during the first 1–2 months
  • CBC with differential (track blast maturation and rising WBC)
  • Tumor-lysis labs (uric acid, potassium, phosphate, calcium, creatinine) during early response
  • Total/indirect bilirubin (UGT1A1 inhibition mimics hyperbilirubinemia)

Key trials & series

  • Stein et al., Blood 2017 — first-in-human AG221-C-001 phase 1/2 (registrational R/R AML data, 40.3% ORR, 7% grade ≥3 differentiation syndrome)
  • Montesinos et al., Blood Adv 2024 — pooled 4-trial analysis defining 10.4% differentiation-syndrome incidence

Clinical pearls

  • Differentiation syndrome — not direct nephrotoxicity — is the reason enasidenib threatens the kidney; treat early with steroids and do not necessarily stop the drug.
  • Indirect hyperbilirubinemia from UGT1A1 inhibition is expected and benign; do not confuse it with hepatorenal or hemolytic processes.
  • A rising WBC during therapy reflects intended blast maturation, not relapse — but it heralds differentiation-syndrome and tumor-lysis risk.
Beyond the kidney — non-renal toxicities· 2 organ systems

Class-level context for the major non-renal toxicities of the IDH2 inhibitor class.

Pulmonary

Pneumonitis, ILD, effusions, hypertension

  • Differentiation syndrome

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

  • QT prolongation
§05

References

8 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

8 references · 2017–2025 · 5 since 2023
202017: 1 citation2018: 1 citation2021: 1 citation2023: 2 citations2024: 2 citations2025: 1 citation201720202025

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkEnasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Stein EM et al. · Blood · 2017 · PMID 28588020First-in-human phase 1/2 registrational trial: 40.3% ORR, differentiation as mechanism of response, 7% grade ≥3 differentiation syndrome.
  2. 2.Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.Montesinos P et al. · Blood Adv · 2024 · PMID 38507688Pooled analysis of 4 trials: 10.4% any-grade differentiation syndrome, risk factors and management.
  3. 3.How I treat acute myeloid leukemia with differentiation therapy.Issa GC et al. · Blood · 2025 · PMID 38976876Practical review of differentiation syndrome across ATRA/ATO and IDH/FLT3 inhibitors, including renal insufficiency and steroid management.
  4. 4.Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia.Fathi AT et al. · Am J Hematol · 2021 · PMID 33625753Review of differentiation syndrome with IDH and FLT3 inhibitors, diagnostic criteria and end-organ (renal) effects.
  5. 5.Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.Dogra R et al. · Anticancer Agents Med Chem · 2018 · PMID 30360730Mechanism, pharmacokinetics and toxicity review (differentiation syndrome, electrolyte changes).
  6. 6.Differentiation Syndrome in Acute Leukemia: APL and Beyond.Woods AC et al. · Cancers (Basel) · 2023 · PMID 37835461Review of differentiation-syndrome pathogenesis including acute renal failure with IDH/retinoid/arsenic agents.
  7. 7.Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.Aiman W et al. · Leuk Res · 2023 · PMID 37100025Systematic review quantifying grade ≥3 differentiation syndrome and QT effects of IDH inhibitors.
  8. 8.Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies.Kala J et al. · Kidney360 · 2024 · PMID 39186376Onconephrology review of AKI mechanisms across targeted agents including IDH inhibitors.
FDA label — boxed warning & renal dosing· boxed warning · 1 kidney table row

Quoted verbatim from this agent's current FDA label (Jan 2025) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: DIFFERENTIATION SYNDROME Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution ( 5.1 , 6.1 ).

Kidney rows of the label's dosage tables

From the Idhifa label (Jan 2025) · DailyMed

The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. Educational only, not medical advice.

Table 1: Dosage Modifications for IDHIFA-Related Toxicities
• Differentiation syndrome• If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring [see Warnings and Precautions (5.1)]. • Interrupt IDHIFA if severe pulmonary symptoms requiring intubation or ventilator support, and/or renal dysfunction persist for more than 48 hours after initiation of corticosteroids [see Warnings and Precautions (5.1)]. • Resume IDHIFA when signs and symptoms improve to Grade 2* or lower.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 3,369 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS outcomes & reporting trend· 24.9% of reports w/ death · 25.6% w/ hospitalization
24.9%

Reported with a death outcome

839 of 3,369 reports

25.6%

Reported with hospitalization

864 of 3,369 reports

Reports per year

  • 2015: 0 reports
  • 2016: 0 reports
  • 2017: 90 reports
  • 2018: 400 reports
  • 2019: 424 reports
  • 2020: 548 reports
  • 2021: 395 reports
  • 2022: 317 reports
  • 2023: 372 reports
  • 2024: 377 reports
  • 2025: 276 reports
  • 2026: 170 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 8 systems · 3,369 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 0.1995% CI 0.09–0.41· 7 AKI reports· IC025 −3.53·AKI is reported less often than for other drugs (CI entirely below 1) — no disproportionate signal.
General / constitutional
Fatigue224Asthenia92Pyrexia74Malaise43Fall42
Gastrointestinal
Nausea197Diarrhoea142Constipation63Vomiting63
Blood & lymphatic
Platelet Count Decreased133White Blood Cell Count Decreased76Haemoglobin Decreased58
Metabolic & electrolyte
Decreased Appetite121
Respiratory
Dyspnoea67Cough41
Nervous system
Dizziness56Headache50
Immune / infection
Pneumonia68
Skin
Rash44
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Enasidenib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Arsenic trioxide

Trisenox · Differentiating agent

Profile

Differentiation syndrome; QT prolongation.

PREATNLYTE
Moderate#1 · 100% phenotype match

Ivosidenib

Tibsovo · IDH1 inhibitor

Profile

Differentiation syndrome → AKI; tumor lysis.

PRELYTEATN
Moderate#2 · 100% phenotype match

Gallium nitrate

Ganite · Antineoplastic metal salt

Profile

Dose-limiting acute tubular necrosis; potentiated by dehydration and concurrent nephrotoxins.

ATNPRELYTE
Moderate#3 · 88% phenotype match

Lifileucel

Amtagvi · Tumor-infiltrating lymphocyte (TIL) therapy

Profile

2024 cellular therapy; high-dose IL-2 conditioning → capillary leak AKI.

PREATNLYTE
Moderate#4 · 85% phenotype match

Tretinoin (ATRA)

Vesanoid · Retinoid (differentiating agent)

Profile

Differentiation syndrome → capillary leak and AKI.

PREATN
Moderate#5 · 84% phenotype match

Tagraxofusp

Elzonris · IL-3 immunotoxin

Profile

Capillary-leak syndrome → AKI.

PREATN
Moderate#6 · 84% phenotype match
Compare Enasidenib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.